Introduction
Treatment options for patients with serious invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are limited. 1 These options include vancomycin and newer agents such as linezolid and daptomycin. 1 Ceftobiprole, a cephalosporin, is currently in Phase III clinical development in the USA and UK, but has recently been approved for use in patients in both Canada and Switzerland. 2 -4 Ceftobiprole is a broad-spectrum cephalosporin with demonstrated in vitro activity against Gram-positive cocci, including MRSA and methicillin-resistant Staphylococcus epidermidis (MRSE), penicillin-resistant Streptococcus pneumoniae, Enterococcus faecalis, Gram-negative bacilli including AmpC-producing Escherichia coli and Pseudomonas aeruginosa but excluding extendedspectrum b-lactamase (ESBL)-producing strains. In single-step and serial passage in vitro resistance development studies, ceftobiprole demonstrated a low propensity to select for resistant subpopulations. 2 Ceftobiprole, like cefepime, is a weak inducer and a poor substrate for AmpC b-lactamases.
Ceftobiprole medocaril, the prodrug of ceftobiprole, is converted by plasma esterases into ceftobiprole in ,30 min. Peak serum concentrations of ceftobiprole observed at the end of a single 30 min infusion were 35.5 mg/L for a 500 mg dose and 59.6 mg/L with a 750 mg dose. 2 The volume of distribution of ceftobiprole is 0.26 L/kg ($18 L), protein binding is $16% and its serum half-life is $3.5 h. Ceftobiprole is renally excreted ($70% in the active form) and systemic clearance correlates with creatinine clearance, meaning that dosage adjustment is required in patients with renal dysfunction.
Ceftobiprole medocaril is being jointly developed by Basilea Pharmaceutica AG and Johnson and Johnson Pharmaceutical Research and Development LLC. 2 -4 Currently, ceftobiprole has completed Phase III trials for complicated skin and skin structure infections due to MRSA, nosocomial pneumonia due to suspected or proven MRSA, while Phase III trials are ongoing for community-acquired pneumonia. The purpose of this study was to assess the pharmacodynamic activity of ceftobiprole and vancomycin against MRSA, vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) using an in vitro model.
Materials and methods

Bacterial strains and culture conditions
Ten S. aureus strains including two methicillin-susceptible S. aureus (MSSA), two community-associated (CA)-MRSA, one healthcareassociated (HA)-MRSA, three VISA and two VRSA were studied. The MSSA, CA-MRSA and HA-MRSA are clinical strains obtained from the CAN-ICU study, a national surveillance study assessing antimicrobial resistance in Canadian intensive care units. 5 The MRSA strains had the following genotypes: CA-MRSA 63307 [CMRSA7/USA400/MW2, Panton -Valentine leucocidin (PVL) þ], CA-MRSA 61592 (CMRSA10/USA300, PVLþ); and HA-MRSA 60392 (CMRSA2/USA100/800/New York, PVL2). 6 VISA and VRSA isolates were obtained through the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) programme, supported under NIAID, NIH Contract No. N01-AI-95359.
For the pharmacodynamic studies, logarithmic phase cultures were prepared by initially suspending several colonies in cationsupplemented Mueller -Hinton broth (Oxoid, Nepean, Ontario, Canada) at a density equivalent to that of a 0.5 McFarland standard (1Â10 8 cfu/mL). This suspension was then diluted 1:100 and 20 mL of the diluted suspension was further diluted in 60 mL of cationsupplemented Mueller-Hinton broth. Following overnight growth at 378C, suspensions were diluted 1:10 and $60 mL of the diluted suspension was added to the in vitro pharmacodynamic model. Viable bacterial counts consistently yielded a starting inoculum of $1Â10 6 cfu/mL.
7,8
Antibiotic preparations and susceptibility testing
Ceftobiprole was obtained as laboratory-grade powder from the manufacturer (Ortho-McNeil, NJ, USA). Vancomycin was purchased commercially. Stock solutions of each agent were prepared and dilutions made according to the CLSI M7-A7 method. 9 Following two subcultures from frozen stock, antimicrobial agent MICs for the strains were determined by the CLSI broth microdilution method. 9 All MIC determinations were performed in triplicate on separate days.
Pharmacokinetics of antibiotics in the in vitro pharmacodynamic model
Experiments were performed simulating peak free drug serum concentrations (fC max ) and fAUC 24 of ceftobiprole and vancomycin achieved in human serum after standard intravenous doses in healthy volunteers [ceftobiprole dose 500 mg every 8 h (fC max , 30 mg/L); vancomycin 1 g dose every 12 h (fC max , 20 mg/L)]. 2, 10, 11 Protein free (f ), also known as unbound, serum concentrations were simulated using known protein binding fractions (ceftobiprole $16%; vancomycin $50%).
2,10,12 Ceftobiprole clearance was simulated using a reported serum half-life of 3.5 h, while for vancomycin a half-life of 8 h was simulated. 2, 10, 11 The pharmacokinetics of ceftobiprole and vancomycin were evaluated by dosing using standard doses in the central compartment and sampling from this compartment at 0, 1, 2, 4, 6, 8, 12, 16 and 24 h. Ceftobiprole concentrations were determined in quadruplicate using E. coli ATCC 25922 as the test organism with a lower limit of quantification of 0.25 mg/L and was linear from 0.25 to 128 mg/L. 7, 8, 13 Specifically, concentrations were determined by measuring the diameters of zones of inhibition and comparing those zone sizes with zones sizes produced by known concentrations from a standard series. The lower and upper detection limits were 0.15 and 256 mg/L, respectively. Both the inter-day and intra-day variation was ,15%. Vancomycin concentrations were assessed using a fluorescence polarization immunoassay (Abbott Diagnostics TDx). 11 The fAUC 24 (mg . h/L) for ceftobiprole and vancomycin was calculated using the trapezoidal rule. 7, 8 The fAUC 24 /MIC was calculated for ceftobiprole and vancomycin for each of the S. aureus strains studied.
In vitro pharmacodynamic model/pharmacodynamic experiments
The in vitro pharmacodynamic model used in this study has been previously described. 7, 8 Logarithmic phase cultures were diluted (1:10) into fresh cation-supplemented Mueller-Hinton broth to achieve a starting inoculum of $1Â10 6 cfu/mL. This initial inoculum was introduced into the central compartment (volume, 610 mL) of the in vitro pharmacodynamic model and exposed to ceftobiprole, simulating free ( protein unbound) serum concentrations obtained after standard 500 mg every 8 h or vancomycin 1 g every 12 h dosing. Pharmacodynamic experiments were performed in ambient air at 378C. At 0, 1, 2, 4, 6, 8, 12, 16 and 24 h, samples were removed from the central compartment and viable bacterial counts carried out by plating serial 10-fold dilutions onto cation-supplemented Mueller -Hinton agar. Plates were incubated overnight at 378C in ambient air. The lowest dilution plated was 0.1 mL of undiluted sample and the lowest level of detection was 200 cfu/mL (20 colonies grown from 0.1 mL of undiluted sample). Antibiotic carryover was minimized by diluting samples withdrawn from the model.
Bacterial inhibition including bactericidal (!3 log 10 killing) activity as well as complete eradication of organisms from the model (below the limit of detection) was assessed at 8, 16 and 24 h and compared for ceftobiprole and vancomycin. Changes in cfu/mL at 24 h were compared using analysis of variance with Tukey's post hoc test. P 0.05 was considered significant.
Results
The susceptibility profiles of the 10 strains of S. aureus studied are presented in (Table 3) .
The pharmacodynamic activity of ceftobiprole against MSSA, CA-MRSA, HA-MRSA, VISA and VRSA is described in Table 4 . For the two MSSA strains, ceftobiprole T . MIC !100% (ceftobiprole MICs, 0.25 mg/L) resulted in bactericidal (!3 log 10 killing) activity within 8 h after administration and completely eradicated the organisms from the model (below the limit of detection) at 24 h (Table 4) (ceftobiprole MICs, 1-2 mg/L) resulted in bactericidal (!3 log 10 killing) activity at 16 and 24 h after administration. No difference in bacterial killing for ceftobiprole was observed between VISA, VRSA and MRSA strains (P .0.05).
The pharmacodynamic activity of vancomycin against MSSA, CA-MRSA, HA-MRSA, VISA and VRSA is described in Table 5 . Against the two MSSA and three MRSA strains, vancomycin fAUC 24 /MIC of 340 (vancomycin MIC, 1 mg/L) resulted in a 0.3 -1.1 log 10 reduction at 8 h, 1.0 -1.4 log 10 reduction at 16 h and 1.8 -2.6 log 10 reduction at 24 h (Table 5) 
Discussion
The first major observation in this study was that ceftobiprole was bactericidal against MSSA, CA-MRSA, HA-MRSA, VISA and VRSA. As CA-MRSA and VISA are emerging pathogens Pharmacodynamics of ceftobiprole versus MRSA, VISA and VRSA worldwide, new bactericidal therapies are needed. 3, 4, 11, 14 Previous work has documented that the MIC 50 and MIC 90 of ceftobiprole for MRSA are 1 and 2 mg/L, respectively. 2, 15, 16 The activity of ceftobiprole versus both CA-MRSA and HA-MRSA is not surprising given that its affinity (IC 50 , 0.9 mg/L) for PBP2a is very high compared with ceftriaxone and ceftazidime (both demonstrate an IC 50 of .50 mg/L). 17 Ceftobiprole in time -kill studies has been reported to be bactericidal against MRSA at 4ÂMIC with no differences in killing between strains of CA-MRSA and HA-MRSA. 16, 18 An interesting finding by Leonard et al., 16 was that ceftobiprole was bactericidal against MRSA at 0.5ÂMIC.
In our in vitro model we focused on the pharmacodynamic parameter T . MIC for ceftobiprole, simulating pharmacokinetics after typical doses used for complicated skin and skin structure infections. 2,11 -13 Other investigators simulating ceftobiprole pharmacodynamics in animals have reported that T . MIC is the pharmacodynamic parameter that is associated with bacterial killing. 13, 19 Using the neutropenic mouse thigh infection model, Craig and Andes 13 reported that ceftobiprole T . MIC of $24% and $32% were required to achieve a static dose and 2 log 10 kill, respectively, for MRSA. In an immunocompromised murine pneumonia model, Laohavaleeson et al. 19 studied the pharmacodynamics of ceftobiprole against a diverse collection of S. aureus strains including MSSA, CA-MRSA and HA-MRSA. These investigators reported that the fT . MIC to achieve a static dose, effective dose 50 (ED 50 ), ED 80 and maximal bacterial killing were 11.0%, 11.9%, 14.6% and $20%, respectively. 19 Consistent with the data in our study, these investigators reported no difference in ceftobiprole bacterial killing between MSSA, CA-MRSA and HA-MRSA (Table 4) . 19 Yin et al. 20 attested to the bactericidal properties of ceftobiprole versus MRSA by studying a rabbit osteomyelitis model and reported that ceftobiprole was able to eradicate MRSA from all infected tibiae. In contrast, these investigators found that only 73% of infected tibiae from vancomycin-and linezolid-treated rabbits had MRSA eradicated. 20 The rapid bactericidal nature of ceftobiprole compared with the lack of bactericidal activity of vancomycin against MRSA is consistent with our study (Tables 4 and 5 ). The good pharmacodynamic properties demonstrated by ceftobiprole against MRSA in vitro are reflected in clinical trials in which rates of clinical and bacteriological eradication of MRSA from patients with complicated skin and skin structure infections of .90% were achieved. 21, 22 Several investigators have reviewed the pharmacokinetic and pharmacodynamic properties of ceftobiprole. 23 -26 Lodise et al., 23 assessed the probability of target attainment (PTA) for ceftobiprole as derived from population pharmacokinetic analysis in 150 subjects. These investigators reported that the PTA of 30% for fT .MIC for pathogens with an MIC of 2 mg/L using ceftobiprole 500 mg every 8 h was $98% and 99% when infused over 30 min or 2 h, respectively. In a recently published report all 1095 S. aureus and 385 MRSA demonstrated ceftobiprole MICs of 2 mg/L. 15 As ceftobiprole is primarily renally eliminated, the PTA will only increase with a decline in renal clearance of the drug. 26 Ceftobiprole's potent activity against S. aureus genotypes including MSSA, MRSA, VISA and VRSA has to be tempered with the report that MRSA can ultimately be made resistant to ceftobiprole in the laboratory. 27 Whether ceftobiprole-resistant MRSA will develop clinically needs to be closely monitored.
The second major observation in this study was that vancomycin was bacteriostatic against MSSA, CA-MRSA, HA-MRSA, VISA and VRSA. Previous work both in vitro and in vivo have repeatedly demonstrated that vancomycin is bacteriostatic versus CA-MRSA and HA-MRSA, and that MRSA re-growth occurs rapidly with vancomycin administration, especially when a high inoculum is used. 11, 28 Rose et al.
11
reported that at high inoculum, MRSA re-growth occurred rapidly even when vancomycin was dosed at 5 g every 12 h. As well, as vancomycin MICs increase from 0.5 to 1 -2 mg/L successful treatment of MRSA bacteraemia has been reported to decrease from 55.6% to 9.5%. 29 As vancomycin is not bactericidal against MRSA, it is not surprising that vancomycin is only marginally better than the growth control (no drug) versus VISA strains and provides no benefit at all for VRSA ( Table 5) .
Limitations of the current study include that the pharmacodynamic model did not simulate a 2 h infusion of ceftobiprole as is used in patients in Canada. 2 Simulating a bolus dose as we did in our model and not optimizing the pharmacodynamics by extending the infusion time to 2 h may have underestimated the bacterial killing of ceftobiprole. Despite this limitation, the ceftobiprole pharmacodynamics simulated resulted in ceftobiprole concentrations exceeding the MIC at all time points and proved to be bactericidal against all strains studied. In addition, as we could not locate an S. aureus strain of any genotype for which the ceftobiprole MIC was .2 mg/L, this precluded a full assessment of ceftobiprole pharmacodynamic activity against strains for which MICs are elevated.
In conclusion, ceftobiprole T .MIC of !100% (ceftobiprole MICs, 2 mg/L) resulted in bactericidal (!3 log 10 killing) activity against MSSA, CA-MRSA, HA-MRSA, VISA and VRSA at 16 and 24 h with no re-growth over the 24 h study period. Vancomycin was bacteriostatic against MSSA, MRSA and VISA, while demonstrating no activity versus VRSA.
Funding
This study was supported in part by the University of Manitoba and Janssen Ortho Inc.
